Can-Fite BioPharma's major customers
Ewopharma accounted for 51% of Can-Fite BioPharma's revenue in FY 2025, up from 30% a year earlier.
Get an email when Can-Fite BioPharma's customer concentration changes
When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.
Major customers of Can-Fite BioPharma
Customers that Can-Fite BioPharma named in its annual report as 10% or more of revenue. A missing year means the customer was below that line or not named.
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Ewopharma | 51% | ▲ from 30% | 5 years | FY 2025 · filed 26 Mar 2026 |
| Chong Kun Dang Pharmaceuticals | 19% | ▲ from 11% | 5 years | FY 2025 · filed 26 Mar 2026 |
| Gebro Holding Gm BH | 19% | ▲ from 11% | 5 years | FY 2025 · filed 26 Mar 2026 |
| Cipher Pharmaceuticals | 11% | from 7% | 5 years | FY 2025 · filed 26 Mar 2026 |
Formerly disclosed
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Vetbiolix | 41% | last FY 2024 | 1 year | FY 2024 · filed 26 Mar 2026 |
About this data
US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.
All companies · Latest dependency shifts · Bulk data and API